The JAK2, CALR, and MPL mutations thus converge on activation of JAK-STAT signaling, particularly through activation of the MPL receptor, and as they by themselves are sufficient to initiate and maintain the MPN phenotype in patients and murine models, they are considered phenotypic driver mutations (Figure 1) [44,45]. Here, JAK2 is linked to myeloproliferative neoplasm.